Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 26
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Fast assessment of resistance to carbapenems and ciprofloxacin of clinical strains of Acinetobacter baumannii

  • Bou, Germán
  • Otero, Fátima María
  • Santiso, Rebeca
  • Tamayo, María
  • Fernández, María Del Cármen
  • Tomás, María Del Mar
  • Gosalbez Berenguer, José Jaime
  • Fernández, José Luís F.
Infections caused by multidrug-resistant Acinetobacter baumannii constitute a major life-threatening problem worldwide, and early adequate antibiotic therapy is decisive for success. For these reasons, rapid detection of antibiotic susceptibility in this pathogen is a clinical challenge. Two variants of the Micromax kit were evaluated for a rapid detection in situ of susceptibility or resistance to meropenem or ciprofloxacin, separately, in 322 clinical isolates. Release of the nucleoid is the criterion of susceptibility to the beta-lactams (carbapenems), whereas diffusion of DNA fragments emerging from the nucleoid characterizes the quinolone activity. All the susceptible and resistant strains were correctly categorized in 100 min according to the MIC results and CLSI criteria. Thus, our technology is a promising tool for rapid identification of carbapenem and quinolone resistance of A. baumannii strains in hospital settings, This work has been supported by grants from the European Community, FP 7, ID: 278232 (MagicBullet), Xunta de Galicia 10CSA916020PR, and by REIPI, Spanish Network for Research in Infectious Diseases (Instituto de Salud Carlos III, RD06/0008/0025) and the Fondo de Investigaciones Sanitarias (PS09/00687) to G.B.
Biblos-e Archivo. Repositorio Institucional de la UAM
Publication Artículo científico (JournalArticle)

Rapid determination of colistin resistance in clinical strains of acinetobacter baumannii by use of the micromax assay

  • Tamayo, María
  • Santiso, Rebeca
  • Otero, Fátima María
  • Bou, Germán
  • Lepe, José Antonio
  • McConnell, Michael J.
  • Cisneros, José Miguel
  • Gosalbez Berenguer, José Jaime
  • Fernández, José Luís F
Colistin is an old antibiotic which has been used as a therapeutic option for carbapenem- and multidrug-resistant Gram-negative bacteria, like Acinetobacter baumannii. This pathogen produces life-threatening infections, mainly in patients admitted to intensive care units. Rapid detection of resistance to colistin may improve patient outcomes and prevent the spread of resistance. For this purpose, Micromax technology was evaluated in four isogenic A. baumannii strains with known mechanisms of resistance to colistin and in 66 isolates (50 susceptible and 16 resistant). Two parameters were determined, DNA fragmentation and cell wall damage. To assess DNA fragmentation, cells trapped in a microgel were incubated with a lysing solution to remove the cell wall, and the released nucleoids were visualized under fluorescence microscopy. Fragmented DNA was observed as spots that diffuse from the nucleoid. To assess cell wall integrity, cells were incubated with a lysis solution which removes only weakened cell walls, resulting in nucleoid release exclusively in affected cells. A dose-response relationship was demonstrated between colistin concentrations and the percentages of bacteria with DNA fragmentation and cell wall damage, antibiotic effects that were delayed and less frequent in resistant strains. Receiver operating characteristic (ROC) curves demonstrated that both DNA fragmentation and cell wall damage were excellent parameters for identifying resistant strains. Obtaining<11% of bacteria with cell wall damage after incubation with 0.5 g/ml colistin identified resistant strains of A. baumannii with 100% sensitivity and 96% specificity. Results were obtained in 3 h 30 min. This is a simple, rapid, and accurate assay for detecting colistin resistance in A. baumannii, with strong potential value in critical clinical situations, This work has been supported by MagicBullet, Xunta de Galicia 10CSA916020PR, and by REIPI, the Spanish Network for Research in Infectious Diseases (Instituto de Salud Carlos III, REIPI RD12/0015) and the Fondo de Investigaciones Sanitarias (FIS PI12/00552) to G.B. M.J.M. is supported by the Subprograma Miguel Servet from the Ministerio de Economía y Competitividad of Spain (CP11/00314). MagicBullet is a project funded by the European Union–Directorate General for Research and Innovation through the Seventh Framework Program for Research and Development (grant agreement 278232) and has been running since 1 January 2012 (36 months’ duration)
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

New Mutations in ADC-Type β-Lactamases From Acinetobacter Spp. Affect Cefoxitin and Ceftazidime Hydrolysis

  • Pérez, Astrid
  • Pérez-Llarena, Francisco J.
  • García, Patricia
  • Kerff, Frédéric
  • Beceiro Casas, Alejandro
  • Galleni, Moreno
  • Bou, Germán
This is a pre-copyedited, author-produced version of an article accepted for publication in Journal of Journal of Antimicrobial Chemotherapy following peer review. The version of record is available online at: https://doi.org/10.1093/JAC/DKU163., [Abstract] Objectives: Two natural variants of ADC-type β-lactamases of Acinetobacter spp., ADC-1 and ADC-5, differ by nine mutations in their protein sequence. ADC-5 hydrolyses cefoxitin better than ADC-1 and the opposite is true for ceftazidime. We produced single and combined mutations in ADC-5 and characterized the variants microbiologically and biochemically to determine which amino acid residues are involved in the hydrolysis of β-lactam antibiotics in this family of β-lactamases. Methods: Site-directed mutagenesis, with blaADC-5 as a source of DNA, was used to generate nine single mutated and three combined mutated enzymes. The proteins (wild-type and derivatives) were then expressed in isogenic conditions in Escherichia coli. MICs of β-lactams were determined using Etest strips. ADC-1, ADC-5, ADC-5-P167S and ADC-5-P167S/D242G/Q163K/G342R were also purified and the kinetic parameters determined for ceftazidime, cefoxitin, cefalotin and ampicillin. Results: Single mutations did not significantly convert the hydrolysis spectrum of the ADC-5 enzyme into that of the ADC-1 enzyme, although among all studied mutants only the quadruple mutant (ADC-5-P167S/D242G/Q163K/G342R) displayed microbiological and biochemical properties consistent with those of ADC-1. Conclusions: Although some single mutations are known to affect cefepime hydrolysis in ADC-type β-lactamases, little is known about ceftazidime and cefoxitin hydrolysis in this family of β-lactamases. Hydrolysis of these antibiotics appears to be positively and negatively affected, respectively, by the Q163K, P167S, D242G and G342R amino acid replacements., This study was funded by grants from the European Community, FP7, ID: 278232 (MagicBullet), and by Plan Nacional de I+D+I 2008–2011 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), cofinanced by the European Development Regional Fund (EDRF) ‘A Way to Achieve Europe’. It has also been funded by the Fondo de Investigación Sanitaria (grant PI12/00552). F. K. is a research associate of the FRS-FNRS (Brussels, Belgium)
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Rapid detection of enterobacteriaceae producing extended spectrum beta-lactamases directly from positive blood cultures by matrix-assisted laser desorption ionization-time of flight mass spectrometry

  • Oviaño, Marina
  • Fernández, Begoña
  • Barba, María José
  • Mouriño, C.
  • Bou, Germán
[Abstract] Bacteria that produce extended-spectrum β-lactamases (ESBLs) are an increasing healthcare problem and their rapid detection is a challenge that must be overcome in order to optimize antimicrobial treatment and patient care. Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MS) has been used to determine resistance to β-lactams, including carbapenems in Enterobacteriaceae, but the methodology has not been fully validated as it remains time-consuming. We aimed to assess whether MALDI-TOF can be used to detect ESBL-producing Enterobacteriaceae from positive blood culture bottles in clinical practice. In the assay, 141 blood cultures were tested, 13 of them were real bacteraemias and 128 corresponded to blood culture bottles seeded with bacterial clinical isolates. Bacteraemias were analysed by MALDI-TOF after a positive growth result and the 128 remaining blood cultures 24 h after the bacterial seeding. β-lactamase activity was determined through the profile of peaks associated with the antibiotics cefotaxime and ceftazidime and its hydrolyzed forms. Clavulanic acid was added to rule out the presence of non-ESBL mechanisms. Overall data show a 99% (103 out of 104) sensitivity in detecting ESBL in positive blood cultures. Data were obtained in 90 min (maximum 150 min). The proposed methodology has a great impact on the early detection of ESBL-producing Enterobacteriaceae from positive blood cultures, being a rapid and efficient method and allowing early administration of an appropriate antibiotic therapy., This study was funded by grants from the European Community, FP 7, ID: 278232 (MagicBullet), and by Plan Nacional de I+D+I 2008-2011 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, the Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0014) co-financed by European Development Regional Fund ‘A Way to achieve Europe’ ERDF, and by the Fondo de Investigación Sanitaria (grant PI12/00552).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Evaluation of MALDI-TOF mass spectrometry for identification of anaerobic bacteria

  • Barba, María José
  • Viña Fernández, Anabel María
  • Oviaño, Marina
  • Fernández, Begoña
  • Velasco, David
  • Bou, Germán
Comparative study, [Abstract] In this study MALDI-TOF MS was evaluated in the identification of anaerobic bacteria comparing it with Rapid ID 32A system. Discrepancies were solved by 16S r-RNA gene sequencing. At the species level MALDI-TOF MS identified 94.82% and Rapid ID 32A 86.67%, showing the superiority of MALDI-TOF MS to conventional methods., This study was funded by the European Community (FP 7, ID:278232, MagicBullet), and by Plan Nacional de I+D+I 2008–2011 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0014)-co-financed by European Development Regional Fund “A Way to achieve Europe” ERDF and, finally by the Fondo de Investigación Sanitaria (grant PI12/00552).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

The Acinetobacter Baumannii OMP33-36 Porin Is a Virulence Factor That Induces Apoptosis and Modulates Autophagy in Human Cells

  • Rumbo, Carlos
  • Tomás, María
  • Fernández-Moreira, Esteban
  • Soares, Nelson C.
  • Carvajal, Micaela
  • Santillana, Elena
  • Beceiro Casas, Alejandro
  • Romero, Antonio
  • Bou, Germán
[Abstract] Acinetobacter baumannii is an extracellular opportunistic human pathogen that is becoming increasingly problematic in hospitals. In the present study, we demonstrate that the A. baumannii Omp 33- to 36-kDa protein (Omp33-36) is a porin that acts as a channel for the passage of water. The protein is found on the cell surface and is released along with other porins in the outer membrane vesicles (OMVs). In immune and connective cell tissue, this protein induced apoptosis by activation of caspases and modulation of autophagy, with the consequent accumulation of p62/SQSTM1 (sequestosome 1) and LC3B-II (confirmed by use of autophagy inhibitors). Blockage of autophagy enables the bacterium to persist intracellularly (inside autophagosomes), with the subsequent development of cytotoxicity. Finally, we used macrophages and a mouse model of systemic infection to confirm that Omp33-36 is a virulence factor in A. baumannii. Overall, the study findings show that Omp33-36 plays an important role in the pathogenesis of A. baumannii infections., This work was supported by Magic Bullet (to G. Bou), a project funded by the European Union's Directorate General for Research and Innovation, through the Seventh Framework Program for Research and Development (grant agreement 278232); the Spanish Network for Research in Infectious Diseases (REIPI-RD12/0015); and Spanish Ministry of Health/FEDER funding (ISCIII-FIS PI12/00552 to G. Bou, FIS PI10/00056 and PI13/02390 to M. Tomás).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Role of Acinetobacter Baumannii UmuD Homologs in Antibiotic Resistance Acquired Through DNA Damage-Induced Mutagenesis

  • Aranda Rodríguez, Jesús
  • López, Mario
  • Leiva, Enoy
  • Magán, Andrés
  • Adler, Ben
  • Bou, Germán
  • Barbé, Jordi
[Abstract] The role of Acinetobacter baumannii ATCC 17978 UmuDC homologs A1S_0636-A1S_0637, A1S_1174-A1S_1173, and A1S_1389 (UmuDAb) in antibiotic resistance acquired through UV-induced mutagenesis was evaluated. Neither the growth rate nor the UV-related survival of any of the three mutants was significantly different from that of the wild-type parental strain. However, all mutants, and especially the umuDAb mutant, were less able to acquire resistance to rifampin and streptomycin through the activities of their error-prone DNA polymerases. Furthermore, in the A. baumannii mutant defective in the umuDAb gene, the spectrum of mutations included a dramatic reduction in the frequency of transition mutations, the mutagenic signature of the DNA polymerase V encoded by umuDC., This study was funded by grants from the Ministerio de Ciencia e Innovación (BFU2011-23478); the European Community, FP 7, ID: 278232 (Magic Bullet); the Ministerio de Ciencia e Innovación, Instituto de Salud Carlos III—cofinanced by the Spanish Network for Research in Infectious Diseases (REIPI RD12/0015) and FIS PI12/00552. J.A. is the recipient of a Sara Borrell postdoctoral grant from the Instituto de Salud Carlos III (Madrid, Spain).
RUC. Repositorio da Universidade da Coruña
Publication Tesis doctoral (DoctoralThesis)

Desarrollo de nuevos procedimientos rápidos y eficaces para evaluar in situ la sensibilidad o resistencia bacteriana a distintos tipos de antibióticos

  • Otero Fariña, Fátima
[Resumen]: La resistencia antibiótica es un grave problema de salud pública mundial. Los antibiogramas clásicos habitualmente requieren 18-24 horas, pero en situaciones críticas puede ser decisiva una caracterización rápida y precisa de la cepa bacteriana.Esta tesis desarrolla procedimientos para determinar la sensibilidad/resistencia antibiótica en bacterias de alta patogenicidad, de forma simple, rápida y eficaz. Todos tienen en común la inmovilización de las bacterias en un microgel para su observación bajo microscopía de fluorescencia.Para cada tipo de antibiótico se estableció y validó un parámetro fenotípico que permite discriminar cepas resistentes de sensibles. Las quinolonas, que inducen roturas del ADN, fueron evaluadas mediante visualización directa de la fragmentación del nucleoide. En el caso de antibióticos que inhiben la síntesis del peptidoglicano, la afectación de la pared bacteriana se determinó mediante la promoción de la liberación del nucleoide o de la elongación celular. La colistina, que actúa sobre la membrana plasmática, mostró afectación secundaria en ADN y pared celular. Los antibióticos que inhiben la síntesis proteica, se evaluaron por prevención de procesos autolíticos inducidos en Gram-positivos y de la elongación por respuesta SOS provocada por mitomicina C en Gram-negativos.Los resultados se obtuvieron entre 40-210 minutos, concordando prácticamente con los antibiogramas estándar., [Resumo]: A resistencia antibiótica é un grave problema de saúde pública mundial. Os antibiogramas clásicos habitualmente requiren 18-24 horas, pero en situacións críticas pode ser decisiva unha caracterización rápida e precisa da cepa bacteriana.Esta tese desenvolve procedementos para determinar a sensibilidade/resistencia antibiótica en bacterias de alta patoxenicidade, de forma simple, rápida e eficaz. Todos teñen en común a inmobilización das bacterias nun microxel para a súa observación baixo microscopía de fluorescencia.Para cada tipo de antibiótico estableceuse e validouse un parámetro fenotípico que permite discriminar cepas resistentes de sensibles. As quinolonas, que inducen roturas do ADN, foron avaliadas mediante visualización directa da fragmentación do nucleoide. No caso de antibióticos que inhiben a síntese do peptidoglicano, a afectación da parede bacteriana determinouse mediante a promoción da liberación do nucleoide ou da elongación celular. A colistina, que actúa sobre a membrana plasmática, mostrou afectación secundaria en ADN e parede celular. Os antibióticos que inhiben a síntese proteica, avaliáronse por prevención de procesos autolíticos inducidos en Gram-positivos e da elongación por resposta SOS provocada por mitomicina C en Gram-negativos.Os resultados obtivéronse entre 40-210 minutos, concordando practicamente cos antibiogramas estándar., [Abstract]: Antibiotic resistance is a serious global public health problem. Classical antibiograms usually require 18-24 hours, but in critical situations a rapid and accurate characterisation of the bacterial strain can be decisive.This thesis develops procedures to determine antibiotic sensitivity/resistance in highly pathogenic bacteria in a simple, fast and efficient way. All of them have in common the immobilisation of the bacteria in a microgel for observation under fluorescence microscopy.For each type of antibiotic, a phenotypic parameter was established and validated to discriminate between resistant and sensitive strains. Quinolones, which induce DNA breaks, were evaluated by direct visualisation of nucleoid fragmentation. For antibiotics that inhibit peptidoglycan synthesis, bacterial wall damage was determined by promoting nucleoid release or cell elongation. Colistin, which acts on the plasma membrane, showed secondary involvement in DNA and cell wall. Antibiotics that inhibit protein synthesis were evaluated for the prevention of autolytic processes induced in Gram-positives and elongation due to SOS response caused by mitomycin C in Gram-negatives.The results were obtained between 40-210 minutes, in close agreement with standard antibiograms., Xunta de Galicia; 10CSA916020PR., Fondo de Investigaciones Sanitarias (FIS); PI14/01346.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Increased antimicrobial resistance in a novel CMY-54 AmpC-type enzyme with a GluLeu217-218 insertion in the Ω-loop

  • Pérez-Llarena, Francisco J.
  • Vázquez-Ucha, Juan Carlos
  • Kerff, Frédéric
  • Zamorano, Laura
  • Miró, Elisenda
  • Póvoa Cabral, María
  • Fleites, Ana
  • Lantero, Marta
  • Martínez-Martínez, Luis
  • Oliver, Antonio
  • Galleni, Moreno
  • Navarro, Ferrán
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] During a Spanish surveillance study, a natural variant of a CMY-type β-lactamase related to CMY-2 with a GluLeu217-218 insertion in the Ω-loop (designated CMY-54) was found to increase the minimum inhibitory concentractions to β-lactams in a clinical strain of Escherichia coli. The aim of this study was to characterize CMY-54 by genetic, microbiological, and biochemical analysis. The blaCMY-54 gene is encoded by a plasmid of around 100 kb that hybridizes with K and FIB probes. The genetic context of blaCMY-54 and blaCMY-2 genes was found to be very similar. E. coli expressing CMY-54 under isogenic conditions showed a clear fourfold to eightfold increase in MICs to penicillins, cefotaxime, ceftazidime, and aztreonam compared with CMY-2. The catalytic efficiencies of pure CMY-2 and CMY-54 proteins correlated with their microbiological parameters. CMY-2 protein was more resistant to thermal denaturation than CMY-54, indicating that the Ω-loop of CMY-54 may be wider and more relaxed and probably enables better accommodation of these antimicrobials. Otherwise, the higher stabilization of CMY-2 may induce a slight reduction of the dynamics of this enzyme and primarily affect the hydrolysis of some of the bulkiest antibiotics. In summary, the GluLeu217-218 insertion observed in CMY-54 compared to CMY-2 produces a β-lactamase with a distinctive catalytic efficacy for β-lactam antimicrobials likely caused by an increased flexibility slightly affecting the active site shape, highlighting the relevance of single mutations on the hydrolytic spectrum in class C β-lactamases., This work was funded by the European Community, FP7, ID:278232 (MagicBullet) and by the Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0006) – cofinanced by European Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014–2020. Additional funding was provided by the Fondo de Investigación Sanitaria (grants PI12/00552, PI14/00059, and PI15/00860) and by the ISCIII: CP13/00226. F.K. is a research associate from the FRS-FNRS (Belgium).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii

  • Beceiro Casas, Alejandro
  • Moreno-Flores, Antonio
  • Fernández, Natalia
  • Vallejo, J. A.
  • Aranda Rodríguez, Jesús
  • Adler, Ben
  • Harper, Marina
  • Boyce, John Dallas
  • Bou, Germán
[Abstract] Two mechanisms of resistance to colistin have been described in Acinetobacter baumannii. One involves complete loss of lipopolysaccharide (LPS), resulting from mutations in lpxA, lpxC, or lpxD, and the second is associated with phosphoethanolamine addition to LPS, mediated through mutations in pmrAB. In order to assess the clinical impacts of both resistance mechanisms, A. baumannii ATCC 19606 and its isogenic derivatives, AL1851 ΔlpxA, AL1852 ΔlpxD, AL1842 ΔlpxC, and ATCC 19606 pmrB, were analyzed for in vitro growth rate, in vitro and in vivo competitive growth, infection of A549 respiratory alveolar epithelial cells, virulence in the Caenorhabditis elegans model, and virulence in a systemic mouse infection model. The in vitro growth rate of the lpx mutants was clearly diminished; furthermore, in vitro and in vivo competitive-growth experiments revealed a reduction in fitness for both mutant types. Infection of A549 cells with ATCC 19606 or the pmrB mutant resulted in greater loss of viability than with lpx mutants. Finally, the lpx mutants were highly attenuated in both the C. elegans and mouse infection models, while the pmrB mutant was attenuated only in the C. elegans model. In summary, while colistin resistance in A. baumannii confers a clear selective advantage in the presence of colistin treatment, it causes a noticeable cost in terms of overall fitness and virulence, with a more striking reduction associated with LPS loss than with phosphoethanolamine addition. Therefore, we hypothesize that colistin resistance mediated by changes in pmrAB will be more likely to arise in clinical settings in patients treated with colistin., This study was funded by grants from the European Community, FP 7 (ID, 278232) (MagicBullet); the Ministerio de Ciencia e Innovación; Instituto de Salud Carlos III, cofinanced by the Spanish Network for Research in Infectious Diseases (REIPI RD12/0015); and Fondo de Investigación Sanitaria (grant PI12/00552).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Genetic and kinetic characterization of the novel AmpC β-lactamases DHA-6 and DHA-7

  • Pérez-Llarena, Francisco J.
  • Zamorano, Laura
  • Kerff, Frédéric
  • Beceiro Casas, Alejandro
  • García, Patricia
  • Miró, Elisenda
  • Larrosa, Nieves
  • Gómez-Bertomeu, Frederic
  • Méndez, José Antonio
  • González-López, Juan José
  • Oliver, Antonio
  • Galleni, Moreno
  • Navarro, Ferrán
  • Bou, Germán
[Abstract] During a Spanish surveillance study, two natural variants of DHA β-lactamases, DHA-6 and DHA-7, were found, with the replacements Ala226Thr and Phe322Ser, respectively, with respect to DHA-1. The DHA-6 and DHA-7 enzymes were isolated from Escherichia coli and Enterobacter cloacae clinical isolates, respectively. The aim of this study was to genetically, microbiologically, and biochemically characterize the DHA-6 and DHA-7 β-lactamases. The blaDHA-6 and blaDHA-7 genes were located in the I1 and HI2 incompatibility group plasmids of 87.3 and 310.4 kb, respectively. The genetic contexts of blaDHA-6 and blaDHA-7 were similar to that already described for the blaDHA-1 gene and included the qnrB4 and aadA genes. The MICs for cephalothin, aztreonam, cefotaxime, and ceftazidime were 8- to 32-fold lower for DHA-6 than for DHA-1 or DHA-7 expressed in the same isogenic E. coli TG1 strain. Interestingly, the MIC for cefoxitin was higher in the DHA-6-expressing transformant than in DHA-1 or DHA-7. Biochemical studies with pure β-lactamases revealed slightly lower catalytic efficiencies of DHA-6 against cephalothin, ceftazidime, and cefotaxime than those of DHA-1 and DHA-7. To understand this behavior, stability experiments were carried out and showed that the DHA-6 protein displayed significantly higher stability than the DHA-1 and DHA-7 enzymes. The proximity of Thr226 to the N terminus in the tertiary protein structure in DHA-6 may promote this stabilization and, consequently, may induce a slight reduction in the dynamic of this enzyme that primarily affects the hydrolysis of some of the bulkiest antibiotics., This study was funded by grant 278232 (MagicBullet) from the European Community, FP7; grant REIPI RD12/0015/014 from the Plan Nacional de I+D+I 2008 to 2011 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases, cofinanced by the European Development Regional Fund (EDRF), A Way to Achieve Europe; and grants PI09/1702 (to J.J.G.-L.) and PI12/00552 (to G.B.) from the Fondo de Investigación Sanitaria.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Rapid detection of antibiotic resistance in gram-negative bacteria through assessment of changes in cellular morphology

  • Otero, Fátima
  • Santiso, Rebeca
  • Tamayo, María
  • Fernández, José Luis
  • Bou, Germán
  • Lepe, José Antonio
  • McConnell, Michael J.
  • Gosálvez, Jaime
  • Cisneros, José Miguel
[Abstract] Rapid antimicrobial susceptibility testing has the potential to improve patient outcomes and reduce healthcare-associated costs. In this study, a novel assay based on bacterial cell elongation after exposure to an antibiotic (ceftazidime) was evaluated for its ability to rapidly detect resistance in Gram-negative bacteria. The assay was used to detect resistance in a large collection of strains containing 320 clinical isolates of Acinetobacter baumannii, 171 clinical isolates of Klebsiella pneumoniae, and 212 clinical isolates of Pseudomonas aeruginosa, and the results were compared to those obtained using standard antimicrobial susceptibility testing methods. The assay identified ceftazidime-resistant strains with 100% sensitivity and 100% specificity for A. baumannii, 100% sensitivity and 97.2% specificity for K. pneumoniae, and with 82.3% sensitivity and 100% specificity for P. aeruginosa. Importantly, results were obtained in 1 hour 15 minutes from exponentially growing cultures. This study demonstrates that changes in cell length are highly correlated with phenotypic antibiotic susceptibility determined using standard susceptibility testing methods. This study therefore provides proof-of-concept that changes in cell morphology can be used as the basis for rapid detection of antibiotic resistance and provides the basis for the development of novel rapid diagnostics for the detection of antibiotic resistance., This work has been supported by MagicBullet, the Fondo de Investigaciones Sanitarias PI14/01346, and by REIPI: Spanish Network for Research in Infectious Diseases (Instituto de Salud Carlos III, RD06/0008/0025). M.J.M. is supported by the Subprograma Miguel Servet from the Ministerio de Economía y Competitividad of Spain (CP11/00314). MagicBullet is a project funded by the European Union-Directorate General for Research and Innovation through the Seventh Framework Program for Research and Development (grant agreement number 278232).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial

  • Pérez Gómez, Astrid
  • Gato, Eva
  • Pérez-Llarena, Francisco J.
  • Fernández-Cuenca, Felipe
  • Gude, María José
  • Oviaño, Marina
  • Pachón, María Eugenia
  • Garnacho-Montero, José
  • González-Galán, Verónica
  • Pascual, Álvaro
  • Cisneros, José Miguel
  • Bou, Germán
[Abstract] Objectives: To characterize the antimicrobial susceptibility, molecular epidemiology and carbapenem resistance mechanisms in Pseudomonas aeruginosa isolates recovered from respiratory tract samples from patients with ventilator-associated pneumonia enrolled in the MagicBullet clinical trial. Methods: Isolates were collected from 53 patients from 12 hospitals in Spain, Italy and Greece. Susceptibility was determined using broth microdilution and Etest. MALDI-TOF MS was used to detect carbapenemase activity and carbapenemases were identified by PCR and sequencing. Molecular epidemiology was investigated using PFGE and MLST. Results: Of the 53 isolates, 2 (3.8%) were considered pandrug resistant (PDR), 19 (35.8%) were XDR and 16 (30.2%) were MDR. Most (88.9%) of the isolates from Greece were MDR, XDR or PDR, whereas fewer of the isolates from Spain (33.3%) and Italy (43.5%) showed antibiotic resistance. Three Greek isolates were resistant to colistin. Overall, the rates of resistance of P. aeruginosa isolates to imipenem, ciprofloxacin, ceftolozane/tazobactam and ceftazidime/avibactam were 64.1%, 54.7%, 22.6% and 24.5%, respectively. All isolates resistant to ceftolozane/tazobactam and ceftazidime/avibactam (Greece, n = 10; and Italy, n = 2) carried blaVIM-2. Spanish isolates were susceptible to the new drug combinations. Forty-eight restriction patterns and 27 STs were documented. Sixty percent of isolates belonged to six STs, including the high-risk clones ST-111, ST-175 and ST-235. Conclusions: MDR/XDR isolates were highly prevalent, particularly in Greece. The most effective antibiotic against P. aeruginosa was colistin, followed by ceftolozane/tazobactam and ceftazidime/avibactam. blaVIM-2 is associated with resistance to ceftolozane/tazobactam and ceftazidime/avibactam, and related to highly resistant phenotypes. ST-111 was the most frequent and disseminated clone and the clonal diversity was lower in XDR and PDR strains., This work was supported by the MagicBullet study. The European Union Directorate-General funded MagicBullet for Research and Innovation through the Seventh Framework Program for Research and Development (grant agreement 278232). Funding was also provided by the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion, Spanish Network for Research in Infectious Diseases (RD16/0016/0006) – co-financed by European Development Regional Fund ‘A way to achieve Europe'. This work was supported by the Fondo de Investigación Sanitaria (grant PI15/00860 to G. B.), integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII). A. P. was supported by grant IJCI-2016-29524.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Nosocomial outbreak of a multiresistant Acinetobacter baumannii expressing OXA-23 carbapenemase in Spain

  • Merino Carballeira, María
  • Poza, Margarita
  • Roca, Ignasi
  • Barba, María José
  • Sousa, María Dolores
  • Vila Estapé, Jordi
  • Bou, Germán
Carbapenem-resistant Acinetobacter baumannii isolates were obtained from 50 patients between July 2011 and July 2012 at the University Hospital A Coruña (NW Spain). These multidrug-resistant isolates, which belonged to a single clone, remained only susceptible to tigecycline, minocycline, and colistin and produced the carbapenem-hydrolyzing oxacillinase, OXA-23. This is the first reported outbreak of OXA-23-producing A. baumannii isolates in Spain., This work was supported by the Spanish Network for the research in infectious diseases (REIPI RD12/0015), Fondo de Investigaciones Sanitarias PI12/00552, from the European Community, FP 7, ID: 278232 (MagicBullet) Unión Europea—Fondo Europeo de Desarrollo Regional (FEDER) to GB and Instituto de Salud Carlos III-Ministerio Economía y Competitividad (PI11/01034) Unión Europea—Fondo Europeo de Desarrollo Regional (FEDER) to MP
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Quantitative Proteomic Analysis of Host—Pathogen Interactions: A Study of Acinetobacter baumannii Responses to Host Airways

  • Méndez Arredondo, José Antonio
  • Mateos, Jesús
  • Beceiro Casas, Alejandro
  • López Díaz, María
  • Tomás, María
  • Poza, Margarita
  • Bou, Germán
Additional files: 1. Workflow of the proteomic experiment -- 2. Histopathology shows signs of consolidated pneumonia in infected animals -- 3. Prediction of exoproteins -- 4. RT-PCR analysis of different genes. Primers and Univesal ProbeLibrary (UPL, Roche) probes used in this study -- 5. Protein identification data., [Abstract] Background: Acinetobacter baumannii is a major health problem. The most common infection caused by A. baumannii is hospital acquired pneumonia, and the associated mortality rate is approximately 50 %. Neither in vivo nor ex vivo expression profiling has been performed at the proteomic or transcriptomic level for pneumonia caused by A. baumannii. In this study, we characterized the proteome of A. baumannii under conditions that simulate those found in the airways, to gain some insight into how A. baumannii adapts to the host and to improve knowledge about the pathogenesis and virulence of this bacterium. A clinical strain of A. baumannii was grown under different conditions: in the presence of bronchoalveolar lavage fluid from infected rats, of RAW 264.7 cells to simulate conditions in the respiratory tract and in control conditions. We used iTRAQ labelling and LC-MALDI-TOF/TOF to investigate how A. baumannii responds on exposure to macrophages/BALF. Results: 179 proteins showed differential expression. In both models, proteins involved in the following processes were over-expressed: (i) pathogenesis and virulence (OmpA, YjjK); (ii) cell wall/membrane/envelope biogenesis (MurC); (iii) energy production and conversion (acetyl-CoA hydrolase); and (iv) translation (50S ribosomal protein L9). Proteins involved in the following were under-expressed: (i) lipid metabolism (short-chain dehydrogenase); (ii) amino acid metabolism and transport (aspartate aminotransferase); (iii) unknown function (DNA-binding protein); and (iv) inorganic ion transport and metabolism (hydroperoxidase). Conclusions: We observed alterations in cell wall synthesis and identified 2 upregulated virulence-associated proteins with >15 peptides/protein in both ex vivo models (OmpA and YjjK), suggesting that these proteins are fundamental for pathogenesis and virulence in the airways. This study is the first comprehensive overview of the ex vivo proteome of A. baumannii and is an important step towards identification of diagnostic biomarkers, novel drug targets and potential vaccine candidates in the fight against pneumonia caused by A. baumannii., This study was funded by grants from the European Community, FP7, ID: 278232 (MagicBullet), and by the Plan Nacional de I+D+I 2008-2011 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015/0014), cofinanced by the European Development Regional Fund (EDRF) “A Way to Achieve Europe.” M. T. and A.B. were financially supported by the Miguel Servet Programme ISCIII-FEDER (CP09/00033 and CP13/00226, respectively). This work was supported by the National Plans for Scientific Research, Development and Technological Innovation 2008-2011 and 2013-2016 and funded by the ISCIII- General Subdirection of Assesment and Promotion of the Research – European Regional Development Fund (ERDF) “A way of making Europe”: PI10/00056 and PI13/02390 to M. T., PI11/01034 to M.P., PI12/00552 to G.B. and PI14/00059 to M.P. and A.B.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial

  • Nowak, J.
  • Zander, E.
  • Stefanik, D.
  • Higgins, Paul G.
  • Roca Subirà, Ignasi
  • Vila Estapé, Jordi
  • McConnell, M. J.
  • Cisneros, José Miguel
  • Seifert, Harald
  • MagicBullet Working Group WP4
Objectives: To investigate the molecular epidemiology, antimicrobial susceptibility and carbapenem resistance determinants of Acinetobacter baumannii isolates from respiratory tract samples of patients diagnosed with ventilator-associated pneumonia (VAP) who were enrolled in the MagicBullet clinical trial. Methods: A. baumannii isolates were prospectively cultured from respiratory tract samples from 65 patients from 15 hospitals in Greece, Italy and Spain. Susceptibility testing was performed by broth microdilution. Carbapenem resistance determinants were identified by PCR and sequencing. Molecular epidemiology was investigated using rep-PCR (DiversiLab) and international clones (IC) were identified using our in-house database. Results: Of 65 isolates, all but two isolates (97%) were resistant to imipenem and these were always associated with an acquired carbapenemase, OXA-23 (80%), OXA-40 (4.6%), OXA-58 (1.5%) or OXA-23/58 (1.5%). Resistance to colistin was 47.7%. Twenty-two isolates were XDR, and 20 isolates were pandrug-resistant (PDR). The majority of isolates clustered with IC2 ( n = 54) with one major subtype comprising isolates from 12 hospitals in the three countries, which included 19 XDR and 16 PDR isolates. Conclusions: Carbapenem resistance rates were very high in A. baumannii recovered from patients with VAP. Almost half of the isolates were colistin resistant, and 42 (64.6%) isolates were XDR or PDR. Rep-PCR confirmed IC2 is the predominant clonal lineage in Europe and suggests the presence of an epidemic XDR/PDR A. baumannii clone that has spread in Greece, Italy and Spain. These data highlight the difficulty in empirical treatment of patients with A. baumannii VAP in centres with a high prevalence of carbapenem-resistant A. baumannii .
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Draft Genome Sequence of JVAP01T, the Type Strain of the Novel Species Acinetobacter dijkshoorniae

  • Fernández Orth, Dietmar
  • Cosgaya Castro, Clara
  • Telli, Murat
  • Mosqueda, Noraida
  • Marí Almirall, Marta
  • Roca Subirà, Ignasi
  • Vila Estapé, Jordi
Here, we report the draft genome sequence of the type strain of Acinetobacter dijkshoorniae, a novel human pathogen within the Acinetobacter calcoaceticus-Acinetobacter baumannii (ACB) complex. Strain JVAP01T has an estimated genome size of 3.9 Mb, exhibits a 38.8% G+C content, and carries a plasmid with the blaNDM-1 carbapenemase gene.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial

  • Nowak, Jennifer
  • Zander, E.
  • Stefanik, Danuta
  • Higgins, Paul G.
  • Roca, Ignasi
  • Vila, Jordi
  • McConnell, Michael J.
  • Cisneros, José Miguel
  • Seifert, Harald
MagicBullet Working Group WP4., [Objectives] To investigate the molecular epidemiology, antimicrobial susceptibility and carbapenem resistance determinants of Acinetobacter baumannii isolates from respiratory tract samples of patients diagnosed with ventilator-associated pneumonia (VAP) who were enrolled in the MagicBullet clinical trial., [Methods] A. baumannii isolates were prospectively cultured from respiratory tract samples from 65 patients from 15 hospitals in Greece, Italy and Spain. Susceptibility testing was performed by broth microdilution. Carbapenem resistance determinants were identified by PCR and sequencing. Molecular epidemiology was investigated using rep-PCR (DiversiLab) and international clones (IC) were identified using our in-house database., [Results] Of 65 isolates, all but two isolates (97%) were resistant to imipenem and these were always associated with an acquired carbapenemase, OXA-23 (80%), OXA-40 (4.6%), OXA-58 (1.5%) or OXA-23/58 (1.5%). Resistance to colistin was 47.7%. Twenty-two isolates were XDR, and 20 isolates were pandrug-resistant (PDR). The majority of isolates clustered with IC2 (n = 54) with one major subtype comprising isolates from 12 hospitals in the three countries, which included 19 XDR and 16 PDR isolates., [Conclusions] Carbapenem resistance rates were very high in A. baumannii recovered from patients with VAP. Almost half of the isolates were colistin resistant, and 42 (64.6%) isolates were XDR or PDR. Rep-PCR confirmed IC2 is the predominant clonal lineage in Europe and suggests the presence of an epidemic XDR/PDR A. baumannii clone that has spread in Greece, Italy and Spain. These data highlight the difficulty in empirical treatment of patients with A. baumannii VAP in centres with a high prevalence of carbapenem-resistant A. baumannii., This work was supported by the MagicBullet study. MagicBullet is a project funded by the European Union Directorate-General for Research and Innovation through the Seventh Framework Program for Research and Development (grant agreement 278232) and has been running since 1 January 2012 (duration, 48 months). Paul G. Higgins was supported by grant FOR2251 from the German Research Council (DFG) (www.acinetobacter.de)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates

  • Testa, Raymond
  • Cantón, Rafael
  • Giani, Tommaso
  • Morosini, María-Isabel
  • Nichols, Wright W.
  • Stefanike, Danuta
  • Rossolini, Gian Maria
  • Nordmann, Patrice
Recent clinical isolates of key Gram-negative and Gram-positive bacteria were collected in 2012 from hospitalised patients in medical centres in four European countries (France, Germany, Italy and Spain) and were tested using standard broth microdilution methodology to assess the impact of 4 mg/L avibactam on the in vitro activities of ceftazidime, ceftaroline and aztreonam. Against Enterobacteriaceae, addition of avibactam significantly enhanced the level of activity of these antimicrobials. MIC90 values (minimum inhibitory concentration that inhibits 90% of the isolates) of ceftazidime, ceftaroline and aztreonam for Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Enterobacter aerogenes, Citrobacter freundii and Morganella morganii were reduced up to 128-fold or greater when combined with avibactam. A two-fold reduction in the MIC90 of ceftazidime to 8 mg/L was noted in Pseudomonas aeruginosa isolates when combined with avibactam, whereas little effect of avibactam was noted on the MIC values of the test compounds when tested against Acinetobacter baumannii isolates. Avibactam had little effect on the excellent activity of ceftazidime, ceftaroline and aztreonam against Haemophilus influenzae. It had no impact on the in vitro activity of ceftazidime and ceftaroline against staphylococci and streptococci. This study demonstrates that addition of avibactam enhances the activities of ceftazidime, ceftaroline and aztreonam against Enterobacteriaceae and P. aeruginosa but not against A. baumannii., This study was funded by a grant from AstraZeneca and Actavis (formerly Forest Laboratories). The research of GMR is funded by the European Commission [grant EvoTar-FP7-HEALTH-F3-2011-2011-282004]. The research of HS at the Institute for Microbiology, Immunology and Hygiene (University Hospital of Cologne, Cologne, Germany) is supported by the German Center for Infection Research (DZIF) and the European Union, Directorate General for Research and Innovation through the Seventh Framework Program for Office of Research and Development [MagicBullet, grant agreement 278232]. The research of RC at the Microbiology Department of Ramón y Cajal University Hospital (Madrid, Spain) is funded by the European Commission [grants R-GNOSIS-FP7-HEALTH-F3-2011-282512, MON4STRAT-FP7-HEALTH-2013-INNOVATION-1-602906-2] and the Instituto de Salud Carlos III of Spain [FIS PI12/00734] and co-financed by the European Development Regional Fund [A Way to Achieve Europe program; Spanish Network for Research in Infectious Diseases grant REIPI RD12/0015].
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Investigation of Novel pmrB and eptA Mutations in Isogenic Acinetobacter baumannii Isolates Associated with Colistin Resistance and Increased Virulence In Vivo

  • Gerson, Stefanie
  • Betts, Jonathan W.
  • Lucaßen, Kai
  • Silva Nodari, Carolina
  • Wille, Julia
  • Josten, Michaele
  • Göttig, Stephan
  • Nowak, Jennifer
  • Stefanik, Danuta
  • Roca, Ignasi
  • Vila, Jordi
  • Cisneros, José Miguel
  • La Ragione, Roberto M.
  • Seifert, Harald
  • Higgins, Paul G.
Colistin resistance in Acinetobacter baumannii is of great concern and is a threat to human health. In this study, we investigate the mechanisms of colistin resistance in four isogenic pairs of A. baumannii isolates displaying an increase in colistin MICs. A mutation in pmrB was detected in each colistin-resistant isolate, three of which were novel (A28V, I232T, and ΔL9-G12). Increased expression of pmrC was shown by semi-quantitative reverse transcription-PCR (qRT-PCR) for three colistin-resistant isolates, and the addition of phosphoethanolamine (PEtN) to lipid A by PmrC was revealed by mass spectrometry. Interestingly, PEtN addition was also observed in some colistin-susceptible isolates, indicating that this resistance mechanism might be strain specific and that other factors could contribute to colistin resistance. Furthermore, the introduction of pmrAB carrying the short amino acid deletion ΔL9-G12 into a pmrAB knockout strain resulted in increased pmrC expression and lipid A modification, but colistin MICs remained unchanged, further supporting the strain specificity of this colistin resistance mechanism. Of note, a mutation in the pmrC homologue eptA and a point mutation in ISAba1 upstream of eptA were associated with colistin resistance and increased eptA expression, which is a hitherto undescribed resistance mechanism. Moreover, no cost of fitness was observed for colistin-resistant isolates, while the virulence of these isolates was increased in a Galleria mellonella infection model. Although the mutations in pmrB were associated with colistin resistance, PEtN addition appears not to be the sole factor leading to colistin resistance, indicating that the mechanism of colistin resistance is far more complex than previously suspected and is potentially strain specific., This work was supported by the German Research Council (DFG)–FOR2251 (www.acinetobacter.de). J. Nowak was supported by the MagicBullet study. MagicBullet is a project funded by the European Union–Directorate General for Research and Innovation through the Seventh Framework Program for Research and Development (grant agreement 278232) and has been running since 1 January 2012 (duration, 48 months). C. S. Nodari was supported by the Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior (CAPES; process number 88881.187573/2018-01)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial

  • Pérez, Astrid
  • Gato, Eva
  • Pérez-Llarena, José
  • Fernández-Cuenca, Felipe
  • Gude, María José
  • Oviaño, María
  • Pachón-Ibáñez, M. E.
  • Garnacho-Montero, José
  • González Galán, Verónica
  • Pascual, Álvaro
  • Cisneros, José Miguel
  • Bou, Germán
[Objectives] To characterize the antimicrobial susceptibility, molecular epidemiology and carbapenem resistance mechanisms in Pseudomonas aeruginosa isolates recovered from respiratory tract samples from patients with ventilator-associated pneumonia enrolled in the MagicBullet clinical trial., [Methods] Isolates were collected from 53 patients from 12 hospitals in Spain, Italy and Greece. Susceptibility was determined using broth microdilution and Etest. MALDI-TOF MS was used to detect carbapenemase activity and carbapenemases were identified by PCR and sequencing. Molecular epidemiology was investigated using PFGE and MLST., [Results] Of the 53 isolates, 2 (3.8%) were considered pandrug resistant (PDR), 19 (35.8%) were XDR and 16 (30.2%) were MDR. Most (88.9%) of the isolates from Greece were MDR, XDR or PDR, whereas fewer of the isolates from Spain (33.3%) and Italy (43.5%) showed antibiotic resistance. Three Greek isolates were resistant to colistin. Overall, the rates of resistance of P. aeruginosa isolates to imipenem, ciprofloxacin, ceftolozane/tazobactam and ceftazidime/avibactam were 64.1%, 54.7%, 22.6% and 24.5%, respectively. All isolates resistant to ceftolozane/tazobactam and ceftazidime/avibactam (Greece, n = 10; and Italy, n = 2) carried blaVIM-2. Spanish isolates were susceptible to the new drug combinations. Forty-eight restriction patterns and 27 STs were documented. Sixty percent of isolates belonged to six STs, including the high-risk clones ST-111, ST-175 and ST-235., [Conclusions] MDR/XDR isolates were highly prevalent, particularly in Greece. The most effective antibiotic against P. aeruginosa was colistin, followed by ceftolozane/tazobactam and ceftazidime/avibactam. blaVIM-2 is associated with resistance to ceftolozane/tazobactam and ceftazidime/avibactam, and related to highly resistant phenotypes. ST-111 was the most frequent and disseminated clone and the clonal diversity was lower in XDR and PDR strains., This work was supported by the MagicBullet study. The European Union Directorate-General funded MagicBullet for Research and Innovation through the Seventh Framework Program for Research and Development (grant agreement 278232). Funding was also provided by the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion, Spanish Network for Research in Infectious Diseases (RD16/0016/0006) – co-financed by European Development Regional Fund ‘A way to achieve Europe'. This work was supported by the Fondo de Investigación Sanitaria (grant PI15/00860 to G. B.), integrated in the Plan Nacional de I+D and funded by the Instituto de Salud Carlos III (ISCIII). A. P. was supported by grant IJCI-2016-29524., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): An investigator-driven, open-label, randomized, noninferiority controlled trial

  • Cisneros, José Miguel
  • Rosso-Fernández, Clara
  • Roca-Oporto, Cristina
  • De Pascale, Gennaro
  • Jiménez-Jorge, Silvia
  • Fernández-Hinojosa, Esteban
  • Matthaiou, Dimitrios K.
  • Ramírez, Paula
  • Ortiz Díaz-Miguel, Ramón
  • Estella, Á.
  • Antonelli, Massimo
  • Dimopoulos, George
  • Garnacho-Montero, Carmen
© The Author(s)., [Background]: Colistin is recommended in the empirical treatment of ventilator-associated pneumonia (VAP) with a high prevalence of carbapenem-resistant gram-negative bacilli (CR-GNB). However, the efficacy and safety of colistin are not well defined. [Methods]: A multicenter prospective randomized trial conducted in 32 European centers compared the efficacy and safety of colistin (4.5 million unit loading dose followed by a maintenance dose of 3 million units every 8 h) versus meropenem (2 g every 8 h), both in combination with levofloxacin (500 mg every 12 h) for 7-14 days in patients with late VAP. Between May 2012 and October 2015, 232 patients were randomly assigned to the 2 treatment groups. The primary endpoint was mortality at 28 days after randomization in the microbiologically modified intention-to-treat (mMITT) population. Secondary outcomes included clinical and microbiological cure, renal function at the end of the treatment, and serious adverse events. The study was interrupted after the interim analysis due to excessive nephrotoxicity in the colistin group; therefore, the sample size was not achieved. [Results]: A total of 157 (67.7%) patients were included in the mMITT population, 36 of whom (22.9%) had VAP caused by CR-GNB. In the mMITT population, no significant difference in mortality between the colistin group (19/82, 23.2%) and the meropenem group (19/75, 25.3%) was observed, with a risk difference of - 2.16 (- 15.59 to 11.26, p = 0.377); the noninferiority of colistin was not demonstrated due to early termination and limited number of patients infected by carbapenem-resistant pathogens. Colistin plus levofloxacin increased the incidence of renal failure (40/120, 33.3%, versus 21/112, 18.8%; p = 0.012) and renal replacement therapy (11/120, 9.1%, versus 2/112, 1.8%; p = 0.015). [Conclusions]: This study did not demonstrate the noninferiority of colistin compared with meropenem, both combined with levofloxacin, in terms of efficacy in the empirical treatment of late VAP but demonstrated the greater nephrotoxicity of colistin. These findings do not support the empirical use of colistin for the treatment of late VAP due to early termination. Trial registration: ClinicalTrials.gov, NCT01292031. Registered 9 February 2011., Funded by the Seventh Framework Program of the European Commission. Magic Bullet grant agreement number 278232.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Diversity of amino acid substitutions in PmrCAB associated with colistin resistance in clinical isolates of Acinetobacter baumannii

  • Gerson, Stefanie
  • Lucaßen, Kai
  • Wille, Julia
  • Silva Nodari, Carolina
  • Stefanik, Danuta
  • Nowak, Jennifer
  • Wille, Thorsten
  • Betts, Jonathan W.
  • Roca, Ignasi
  • Vila, Jordi
  • Cisneros, José Miguel
  • Seifert, Harald
  • Higgins, Paul G.
This study aimed to investigate the mechanisms of colistin resistance in 64 Acinetobacter baumannii isolates obtained from patients with ventilator-associated pneumonia hospitalised in Greece, Italy and Spain. In total, 31 A. baumannii isolates were colistin-resistant. Several novel amino acid substitutions in PmrCAB were found in 27 colistin-resistant A. baumannii. Most substitutions were detected in PmrB, indicating the importance of the histidine kinase for colistin resistance. In two colistin-resistant isolates, 93 amino acid changes were observed in PmrCAB compared with A. baumannii ACICU, and homologous recombination across different clonal lineages was suggested. Analysis of gene expression revealed increased pmrC expression in isolates harbouring pmrCAB mutations. Complementation of A. baumannii ATCC 19606 and ATCC 17978 with a pmrAB variant revealed increased pmrC expression but unchanged colistin MICs, indicating additional unknown factors associated with colistin resistance. Moreover, a combination of PmrB and PmrC alterations was associated with very high colistin MICs, suggesting accumulation of mutations as the mechanism for high-level resistance. The pmrC homologue eptA was detected in 29 colistin-susceptible and 26 colistin-resistant isolates. ISAba1 was found upstream of eptA in eight colistin-susceptible and one colistin-resistant isolate and eptA was disrupted by ISAba125 in two colistin-resistant isolates. Whilst in most isolates an association of eptA with colistin resistance was excluded, in one isolate an amino acid substitution in EptA (R127L) combined with a point mutation in ISAba1 upstream of eptA contributed to elevated colistin MICs. This study helps to gain an insight into the diversity and complexity of colistin resistance in A. baumannii., This work was supported by the German Research Council (DFG) – FOR2251 (www.acinetobacter.de). JN was supported by the MagicBullet study. MagicBullet is a project funded by the European Union–Directorate General for Research and Innovation through the Seventh Framework Program for Research and Development [grant agreement 278232] and has been running since 1 January 2012 (duration, 48 months). CSN was supported by the Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior (CAPES) [process no. 88881.187573/2018-01]. IR was supported by the Department of Health, Generalitat de Catalunya [SLT002/16/00349].
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Draft Genome Sequence of JVAP01T, the Type Strain of the Novel Species Acinetobacter dijkshoorniae

  • Fernández Orth, Dietmar
  • Cosgaya Castro, Clara
  • Telli, Murat
  • Mosqueda, Noraida
  • Marí Almirall, Marta
  • Roca Subirà, Ignasi
  • Vila Estapé, Jordi
Here, we report the draft genome sequence of the type strain of Acinetobacter dijkshoorniae, a novel human pathogen within the Acinetobacter calcoaceticus-Acinetobacter baumannii (ACB) complex. Strain JVAP01T has an estimated genome size of 3.9 Mb, exhibits a 38.8% G+C content, and carries a plasmid with the blaNDM-1 carbapenemase gene.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial

  • Nowak, J.
  • Zander, E.
  • Stefanik, D.
  • Higgins, Paul G.
  • Roca Subirà, Ignasi
  • Vila Estapé, Jordi
  • McConnell, M. J.
  • Cisneros, José Miguel
  • Seifert, Harald
  • MagicBullet Working Group WP4
Objectives: To investigate the molecular epidemiology, antimicrobial susceptibility and carbapenem resistance determinants of Acinetobacter baumannii isolates from respiratory tract samples of patients diagnosed with ventilator-associated pneumonia (VAP) who were enrolled in the MagicBullet clinical trial. Methods: A. baumannii isolates were prospectively cultured from respiratory tract samples from 65 patients from 15 hospitals in Greece, Italy and Spain. Susceptibility testing was performed by broth microdilution. Carbapenem resistance determinants were identified by PCR and sequencing. Molecular epidemiology was investigated using rep-PCR (DiversiLab) and international clones (IC) were identified using our in-house database. Results: Of 65 isolates, all but two isolates (97%) were resistant to imipenem and these were always associated with an acquired carbapenemase, OXA-23 (80%), OXA-40 (4.6%), OXA-58 (1.5%) or OXA-23/58 (1.5%). Resistance to colistin was 47.7%. Twenty-two isolates were XDR, and 20 isolates were pandrug-resistant (PDR). The majority of isolates clustered with IC2 ( n = 54) with one major subtype comprising isolates from 12 hospitals in the three countries, which included 19 XDR and 16 PDR isolates. Conclusions: Carbapenem resistance rates were very high in A. baumannii recovered from patients with VAP. Almost half of the isolates were colistin resistant, and 42 (64.6%) isolates were XDR or PDR. Rep-PCR confirmed IC2 is the predominant clonal lineage in Europe and suggests the presence of an epidemic XDR/PDR A. baumannii clone that has spread in Greece, Italy and Spain. These data highlight the difficulty in empirical treatment of patients with A. baumannii VAP in centres with a high prevalence of carbapenem-resistant A. baumannii .
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Increased Antimicrobial Resistance in a Novel CMY-54 AmpC-Type Enzyme with a GluLeu217-218 Insertion in the Ω-Loop

  • Pérez-Llarena, Francisco José
  • Vázquez-Ucha, Juan Carlos
  • Kerff, Frédéric
  • Zamorano, Laura
  • Miró, Elisenda|||0000-0003-2781-6926
  • Cabral, María Póvoa
  • Fleites, Ana
  • Lantero, Marta
  • Martínez-Martínez, Luis
  • Oliver, Antonio|||0000-0001-9327-1894
  • Galleni, Moreno
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Beceiro, Alejandro
  • Bou, German|||0000-0001-8837-0062
During a Spanish surveillance study, a natural variant of a CMY-type β-lactamase related to CMY-2 with a GluLeu217-218 insertion in the Ω-loop (designated CMY-54) was found to increase the minimum inhibitory concentractions to β-lactams in a clinical strain of Escherichia coli. The aim of this study was to characterize CMY-54 by genetic, microbiological, and biochemical analysis. The blaCMY-54 gene is encoded by a plasmid of around 100 kb that hybridizes with K and FIB probes. The genetic context of blaCMY-54 and blaCMY-2 genes was found to be very similar. E. coli expressing CMY-54 under isogenic conditions showed a clear fourfold to eightfold increase in MICs to penicillins, cefotaxime, ceftazidime, and aztreonam compared with CMY-2. The catalytic efficiencies of pure CMY-2 and CMY-54 proteins correlated with their microbiological parameters. CMY-2 protein was more resistant to thermal denaturation than CMY-54, indicating that the Ω-loop of CMY-54 may be wider and more relaxed and probably enables better accommodation of these antimicrobials. Otherwise, the higher stabilization of CMY-2 may induce a slight reduction of the dynamics of this enzyme and primarily affect the hydrolysis of some of the bulkiest antibiotics. In summary, the GluLeu217-218 insertion observed in CMY-54 compared to CMY-2 produces a β-lactamase with a distinctive catalytic efficacy for β-lactam antimicrobials likely caused by an increased flexibility slightly affecting the active site shape, highlighting the relevance of single mutations on the hydrolytic spectrum in class C β-lactamases.